TABLE OF CONTENTS
1 INTRODUCTION 58
1.1 OBJECTIVES OF THE STUDY 58
1.2 MARKET DEFINITION 58
1.3 OVERVIEW OF THE GLOBAL DRUG MODELING SOFTWARE MARKET 58
1.4 CURRENCY AND PRICING 60
1.5 LIMITATIONS 60
1.6 MARKETS COVERED 60
2 MARKET SEGMENTATION 63
2.1 MARKETS COVERED 63
2.2 GEOGRAPHICAL SCOPE 64
2.3 YEARS CONSIDERED FOR THE STUDY 65
2.4 DBMR TRIPOD DATA VALIDATION MODEL 66
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 69
2.6 MULTIVARIATE MODELING 70
2.7 COMPONENT LIFELINE CURVE 70
2.8 DBMR MARKET POSITION GRID 71
2.9 VENDOR SHARE ANALYSIS 72
2.10 MARKET APPLICATION COVERAGE GRID 73
2.11 SECONDARY SOURCES 74
2.12 ASSUMPTIONS 74
3 EXECUTIVE SUMMARY 75
3.1 PORTER'S FIVE FORCES MODEL 81
3.2 VALUE CHAIN ANALYSIS 82
3.3 REGULATORY STANDARDS 83
3.4 TECHNOLOGICAL TRENDS 84
3.5 BENEFITS OF DRUG MODELING SOFTWARE 85
4 MARKET OVERVIEW 86
4.1 DRIVERS 88
4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 88
4.1.2 RISING DEMAND FOR NOVEL THERAPIES 90
4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 91
4.2 RESTRAINTS 92
4.2.1 LACK OF QUALITY DATA BASE 92
4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 92
4.3 OPPORTUNITIES 93
4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 93
4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 94
4.4 CHALLENGES 94
4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 94
4.4.2 CHALLENGES WITH MODEL INTERPRETATION 95
5 GLOBAL DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 96
5.1 OVERVIEW 97
5.1.1 SOFTWARE 100
5.1.1.1 INTEGRATED 101
5.1.1.2 STANDALONE 101
5.1.1.3 LIGAND BASED 101
5.1.1.4 STRUCTURE BASED 101
5.2 SERVICES 101
5.2.1 PROFESSIONAL SERVICES 102
5.2.1.1 CONSULTING AND TRAINING 103
5.2.1.2 INTEGRATION AND IMPLEMENTATION 103
5.2.1.3 SUPPORT AND MAINTENANCE 103
5.2.2 MANAGED SERVICES 103
6 GLOBAL DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 104
6.1 OVERVIEW 105
6.2 WINDOWS 108
6.3 LINUX 108
6.4 MAC OS 109
6.5 OTHERS 110
7 GLOBAL DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 111
7.1 OVERVIEW 112
7.2 CLOUD BASED 115
7.3 HYBRID-BASED 115
7.4 ON-PREMISES 116
8 GLOBAL DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 117
8.1 OVERVIEW 118
8.2 LARGE ENTERPRISE SIZE 121
8.3 SMALL & MEDIUM ENTERPRISE SIZE 121
9 GLOBAL DRUG MODELING SOFTWARE MARKET, BY APPLICATION 123
9.1 OVERVIEW 124
9.2 GRAPHICAL MOLECULAR MODELING 127
9.3 GENE SEQUENCE ANALYSIS 127
9.4 PROTEIN MODELING 128
9.5 MODELING CRYSTAL STRUCTURES 129
9.6 CHEMINFORMATICS 130
9.7 HIGH THROUGHPUT VIRTUAL SCREENING 131
9.8 GAS & SOLUTION PHASE REACTION 131
9.9 MEDICAL IMAGING 132
9.10 OTHERS 133
10 GLOBAL DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 134
10.1 OVERVIEW 135
10.2 SUBSCRIPTION BASED 138
10.2.1 ANNUALLY SUBSCRIPTION 139
10.2.2 MONTHLY SUBSCRIPTION 139
10.3 ONE-TIME LICENSE 139
10.3.1 GROUP LICENSE 140
10.3.2 DESKTOP LICENSE 140
10.3.3 OTHERS 140
11 GLOBAL DRUG MODELING SOFTWARE MARKET, BY END USER 141
11.1 OVERVIEW 142
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 145
11.2.1 LARGE ENTERPRISE SIZE 146
11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 146
11.3 CONTRACT RESEARCH ORGANIZATIONS 146
11.3.1 LARGE ENTERPRISE SIZE 147
11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 147
11.4 RESEARCH INSTITUTES 147
11.4.1 LARGE ENTERPRISE SIZE 148
11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 148
11.5 REGULATORY AUTHORITIES 148
11.5.1 LARGE ENTERPRISE SIZE 149
11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 150
11.6 OTHERS 150
11.6.1 LARGE ENTERPRISE SIZE 151
11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 151
12 GLOBAL DRUG MODELING SOFTWARE MARKET, BY REGION 152
12.1 OVERVIEW 153
12.2 NORTH AMERICA 159
12.2.1 U.S. 169
12.2.2 CANADA 174
12.2.3 MEXICO 179
12.3 EUROPE 184
12.3.1 GERMANY 195
12.3.2 FRANCE 200
12.3.3 U.K. 205
12.3.4 ITALY 210
12.3.5 RUSSIA 215
12.3.6 SPAIN 220
12.3.7 TURKEY 225
12.3.8 NETHERLANDS 230
12.3.9 SWITZERLAND 235
12.3.10 BELGIUM 240
12.3.11 POLAND 245
12.3.12 SWEDEN 250
12.3.13 DENMARK 255
12.3.14 FINLAND 260
12.3.15 NORWAY 265
12.3.16 REST OF EUROPE 270
12.4 ASIA-PACIFIC 271
12.4.1 CHINA 282
12.4.2 JAPAN 287
12.4.3 SOUTH KOREA 292
12.4.4 INDIA 297
12.4.5 AUSTRALIA 302
12.4.6 SINGAPORE 307
12.4.7 THAILAND 312
12.4.8 INDONESIA 317
12.4.9 PHILIPPINES 322
12.4.10 MALAYSIA 327
12.4.11 NEW ZEALAND 332
12.4.12 VIETNAM 337
12.4.13 TAIWAN 342
12.4.14 REST OF ASIA-PACIFIC 347
12.5 SOUTH AMERICA 348
12.5.1 BRAZIL 359
12.5.2 ARGENTINA 364
12.5.3 REST OF SOUTH AMERICA 369
12.6 MIDDLE EAST AND AFRICA 370
12.6.1 SOUTH AFRICA 380
12.6.2 SAUDI ARABIA 385
12.6.3 U.A.E. 390
12.6.4 EGYPT 395
12.6.5 ISRAEL 400
12.6.6 OMAN 405
12.6.7 BAHRAIN 410
12.6.8 KUWAIT 415
12.6.9 QATAR 420
12.6.10 REST OF MIDDLE EAST AND AFRICA 425
13 GLOBAL DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 426
13.1 COMPANY SHARE ANALYSIS: GLOBAL 426
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 427
13.3 COMPANY SHARE ANALYSIS: EUROPE 428
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 429
14 SWOT ANALYSIS 430
15 GLOBAL DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 431
15.1 DASSAULT SYSTEMES 431
15.1.1 COMPANY SNAPSHOT 431
15.1.2 REVENUE ANALYSIS 431
15.1.3 COMPANY SHARE ANALYSIS 432
15.1.4 PRODUCT PORTFOLIO 432
15.1.5 RECENT DEVELOPMENT 432
15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 433
15.2.1 COMPANY SNAPSHOT 433
15.2.2 REVENUE ANALYSIS 433
15.2.3 COMPANY SHARE ANALYSIS 434
15.2.4 PRODUCT PORTFOLIO 434
15.2.5 RECENT DEVELOPMENTS 434
15.3 CERTARA, USA. 435
15.3.1 COMPANY SNAPSHOT 435
15.3.2 REVENUE ANALYSIS 435
15.3.3 COMPANY SHARE ANALYSIS 436
15.3.4 PRODUCT PORTFOLIO 436
15.3.5 RECENT DEVELOPMENTS 436
15.4 SCHRDINGER, INC. 437
15.4.1 COMPANY SNAPSHOT 437
15.4.2 REVENUE ANALYSIS 437
15.4.3 COMPANY SHARE ANALYSIS 438
15.4.4 PRODUCT PORTFOLIO 438
15.4.5 RECENT DEVELOPMENT 438
15.5 CRESSET. 439
15.5.1 COMPANY SNAPSHOT 439
15.5.2 COMPANY SHARE ANALYSIS 439
15.5.3 PRODUCT PORTFOLIO 440
15.5.4 RECENT DEVELOPMENTS 440
15.6 ACELLERA LTD 441
15.6.1 COMPANY SNAPSHOT 441
15.6.2 PRODUCT PORTFOLIO 441
15.6.3 RECENT DEVELOPMENTS 441
15.7 ARGUSLAB 442
15.7.1 COMPANY SNAPSHOT 442
15.7.2 PRODUCT PORTFOLIO 442
15.7.3 RECENT DEVELOPMENT 442
15.8 ATOMWISE INC. 443
15.8.1 COMPANY SNAPSHOT 443
15.8.2 PRODUCT PORTFOLIO 443
15.8.3 RECENT DEVELOPMENT 443
15.9 BC PLATFORMS 444
15.9.1 COMPANY SNAPSHOT 444
15.9.2 PRODUCT PORTFOLIO 444
15.9.3 RECENT DEVELOPMENTS 445
15.10 BIOSOLVEIT GMBH 446
15.10.1 COMPANY SNAPSHOT 446
15.10.2 PRODUCT PORTFOLIO 446
15.10.3 RECENT DEVELOPMENT 446
15.11 DOTMATICS 447
15.11.1 COMPANY SNAPSHOT 447
15.11.2 PRODUCT PORTFOLIO 447
15.11.3 RECENT DEVELOPMENTS 448
15.12 GENECODE 449
15.12.1 COMPANY SNAPSHOT 449
15.12.2 PRODUCT PORTFOLIO 449
15.12.3 RECENT DEVELOPMENT 449
15.13 INSILICOTRIALS TECHNOLOGIES. 450
15.13.1 COMPANY SNAPSHOT 450
15.13.2 PRODUCT PORTFOLIO 450
15.13.3 RECENT DEVELOPMENTS 451
15.14 NANOME INC. 452
15.14.1 COMPANY SNAPSHOT 452
15.14.2 PRODUCT PORTFOLIO 452
15.14.3 RECENT DEVELOPMENT 452
15.15 OPTIBRIUM, LTD. 453
15.15.1 COMPANY SNAPSHOT 453
15.15.2 PRODUCT PORTFOLIO 453
15.15.3 RECENT DEVELOPMENT 453
15.16 PHARMACELERA 454
15.16.1 COMPANY SNAPSHOT 454
15.16.2 PRODUCT PORTFOLIO 454
15.16.3 RECENT DEVELOPMENT 454
15.17 SIMULATIONS PLUS. 455
15.17.1 COMPANY SNAPSHOT 455
15.17.2 REVENUE ANALYSIS 456
15.17.3 COMPANY SHARE ANALYSIS 457
15.17.4 PRODUCT PORTFOLIO 457
15.17.5 RECENT DEVELOPMENT 458
15.18 THE SCRIPPS RESEARCH INSTITUTE 459
15.18.1 COMPANY SNAPSHOT 459
15.18.2 PRODUCT PORTFOLIO 459
15.18.3 RECENT DEVELOPMENT 459
15.19 VERISIM LIFE. 460
15.19.1 COMPANY SNAPSHOT 460
15.19.2 PRODUCT PORTFOLIO 460
15.19.3 RECENT DEVELOPMENTS 460

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.